Temporal arteritis (TA) is a vasculitis involving mainly cranial branches of the aorta that can lead to ischemic complications such as amaurosis or ischemic stroke. Increment in the platelet count has been described in the acute period of the disease. We studied retrospectively the platelet count in patients with TA, its association with ischemic complications and quantified its response to therapy. We found thrombocytosis in 44% of 34 patients with TA, with a mean reduction in the platelet count of 25.1% after therapy. We were also able to quantify the increment in the platelet count at the onset of the disease and its response to prednisone in a group of 5 patients. We did not find any relation between platelet count and ischemic complications of the disease or the result of the temporal artery biopsy. In conclusion TA is associated with an increase in the platelet count, with a 25% reduction after prednisone therapy. These two determinations are not related to ischemic complications of the disease.

Keywords:
Giant cell (temporal) arteritis, Thrombocytosis, Vasculitis, Platelets
1.
Bergstrom AL, Bengtsson BA, Olsson LB, Malmvall BE, Kutti J: Thrombokinetics in giant cell arteritis, with special reference to corticosteroid therapy. Ann Rheum Dis 1979;38:244–247.
2.
Giordano M: Thrombocytosis in giant cell arteritis. Ann Rheum Dis 1980;39:298.
3.
De Keyser J, De Klippel N, Ebinger G: Thrombocytosis and ischaemic complications in giant cell arteritis. BMJ 1991;303:825.
4.
Gibb WR, Urry PA, Lees AJ: Giant cell arteritis with spinal cord infarction and basilar artery thrombosis. J Neurol Neurosurg Psychiatry 1985;48:945–948.
5.
Price N, Clearkin LG: Thrombocytosis and giant cell arteritis. Lancet 1994;343:672.
6.
Krishna R, Kosmorksy GS: Implications of thrombocytosis in giant cell arteritis. Am J Ophthalmol 1997;124:103.
7.
Seyfarth B, Harten P, Loffler H: Thrombocytosis in polymyalgia rheumatica. Dtsch Med Wochenschr 1996;121:1255–1260.
8.
Cid MC, Font C, Oristrell J, Sierra A, Coll-Vinent B, Lopez-Soto A, Vilaseca J, Urbano-Marquez A, Grau J: Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 1998;41:26–32.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.